FDA Clears Dexcom G7: The Most Accurate Continuous Glucose Monitoring System.

(CTN News) – In the U.S., the Dexcom G7 has been cleared for people with all types of diabetes ages two and older. This allows more people than ever to benefit from the benefits of a powerful yet simple diabetes management solution.

• In fact, Dexcom G7 has an overall MARD of 8.2%, making it the most accurate CGM cleared by the FDA1, following the clinically proven performance of Dexcom CGM.

• This is because it has been clinically proven to lower A1C, reduce hyperglycemia, and increase time in range1,2.

• In addition to being cleared as an integrated continuous glucose monitoring (iCGM) system, Dexcom G7 will be incorporated into the largest connected CGM ecosystem in the world1 with its real-time connectivity, which allows it to drive integrated insulin delivery systems, connect with wearables like Apple Watches, and integrate with popular digital health applications.

• Due to Dexcom’s position as the most covered CGM system on the market4, Dexcom users typically pay less per month than those who use other CGM systems1.

Announcing today’s release of the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with diabetes ages two years and older, DexCom, Inc. (NASDAQ:DXCM) announced that the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring system for individuals suffering from all types of diabetes ages two years and older.

With the Dexcom G7, you can now have a more powerful and easier to use diabetic management system with a small, all-in-one wearable without the need for finger sticks or scanning.

The photo below was taken by Business Wire (Source: Business Wire)

As Kevin Sayer, chairman, president and CEO of Dexcom, explains, there’s a reason Dexcom’s real-time CGMs are the most popular on the market.

The technology we’ve developed for the last decade has enabled us to deliver a simple user experience and improved accuracy and precision, giving more positive a greater sense of control over their diabetes compared to what they could achieve with previous generations of sensors.

During the process of designing G7, our goal was to make the most powerful, easiest-to-use CGM available for people with diabetes, regardless of whether they had Type 1 or Type 2 diabetes.

As far as that promise is concerned, G7 lives up to it. Having been cleared by the FDA, we anticipate making G7 commercially available in the coming months as soon as it has received approval from the agency.

SEE ALSO:

US Stocks Open Higher After Initial Claims Show a Slight Increase